-
Phase 2
-
-
18-70Age Range
-
Active, Not Recruiting
Active, Not Recruiting
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
Inclusion Criteria: - Diagnosis of plaque psoriasis (PsO) for ≥ 6 months - Body mass index 18 to 40 kg/m^2 and total body weight > 50 kg (110 lbs) - Deemed by Investigator to be eligible for phototherapy or systemic therapy - Psoriatic plaques must cover ≥ 10% of body surface area at baseline - Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline Exclusion Criteria: - Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic) - Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment - Any significant acute or chronic medical illness Other protocol-defined inclusion/exclusion criteria apply
Experimental: BMS-986322 Dose 1
Experimental: BMS-986322 Dose 2
Experimental: BMS-986322 Dose 3
Placebo Comparator: Placebo